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1  | INTRODUCTION
SUMOylation is a highly dynamic post-translational modification of 
lysine residues in target proteins. SUMOylation and deSUMOylation 
of specific proteins plays key roles in the signalling pathways involved 
in nearly all aspects of neuronal form and function (Henley, Craig, 
& Wilkinson, 2014; Schorova & Martin, 2016). SUMO modification 
of nuclear proteins has been extensively characterized (Jentsch & 
Psakhye, 2013), but multiple proteins in extranuclear compartments 
are also subject to SUMO modification, although in many cases a pre-
cise understanding of the mechanisms and consequences of these 
SUMOylation events is, as yet, less well established (Luo et al., 2013).
There have been a number of reviews and commentaries about 
SUMOylation of extranuclear proteins in neurons, most recently 
(Henley, Carmichael, & Wilkinson, 2018). However, this is a rapidly 
moving area of neuroscience and several new proteins that have 
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Abstract
SUMOylation is a post-translational modification that regulates protein signalling and 
complex formation by adjusting the conformation or protein–protein interactions of 
the substrate protein. There is a compelling and rapidly expanding body of evidence 
that, in addition to SUMOylation of nuclear proteins, SUMOylation of extranuclear 
proteins contributes to the control of neuronal development, neuronal stress re-
sponses and synaptic transmission and plasticity. In this brief review we provide an 
update of recent developments in the identification of synaptic and synapse-associ-
ated SUMO target proteins and discuss the cell biological and functional implications 
of these discoveries.
K E Y W O R D S
GTPases, ion channels, SUMOylation, synaptic plasticity, synaptic proteins
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direct relevance to synaptic function and dysfunction have recently 
been identified and/or validated as SUMO targets.
Here we focus predominantly on the SUMOylation of these 
recently identified synaptic and synapse-associated proteins and 
also on targets that have not been extensively covered in previous 
reviews. This is not an exhaustive list, rather we have arranged the 
SUMO substrates into classes of proteins and discuss how these new 
findings add to our understanding of how SUMOylation can regu-
late a wide range of physiological and pathophysiological processes 
in neurons.
2  | SUMO conjugation and 
deconjugation—a brief over view
In mammals there are three validated SUMO paralogues, SUMO1-3. 
SUMOs are ~ 11kD proteins that are covalently conjugated to ly-
sine residues in target proteins by an enzymatic cascade analogous 
to, but distinct from, the ubiquitin pathway (for extensive reviews 
of the SUMO pathway see (Flotho & Melchior, 2013; Hay, 2005; 
Wilkinson & Henley, 2010; Wilkinson, Nakamura, & Henley, 2010)). 
Briefly, SUMO2 and 3 are highly homologous, differing in only 3 
amino acids, and are therefore collectively referred to as SUMO2/3, 
but SUMO2 and SUMO3 are only ∼48% identical to SUMO1. SUMO 
proteins are initially synthesized as inactive precursors that are first 
cleaved by a member of the SUMO protease family of proteins to 
expose a C-terminal di-glycine motif that is required for conjuga-
tion. SUMO is then activated for conjugation in an ATP-dependent 
manner by the E1 enzyme, a dimer of SAE1/2, before loading onto 
Ubc9, the sole identified E2-conjugating enzyme for SUMOylation. 
SUMO is then conjugated to the target lysine by Ubc9, a process 
that is facilitated in vivo by a number of identified E3 enzymes. Once 
conjugated, SUMO can be removed from target proteins by the ac-
tions of SUMO proteases, the most well characterized of which 
are the Sentrin/SUMO-specific proteases (SENP1-3, 5–7). Thus, 
the dynamic balance between SUMO conjugation, mediated by a 
restricted set of SUMOylation enzymes, and deSUMOylation me-
diated by SUMO proteases, controls substrate protein properties.
3  | Expression and compar tmental izat ion of 
SUMOylation and deSUMOylation enzymes 
in neurons
Neurons are morphologically complex, highly compartmentalized and 
exquisitely activity-sensitive cells. The vast array of spatio-temporally 
regulated events in neurons requires the sophisticated coordination 
of protein trafficking, retention and turnover. Given the wide accept-
ance of the importance of extranuclear protein SUMOylation, includ-
ing at synapses, how SUMO enzymes are localized and regulated in 
these compartments is an important but still poorly understood field.
A recent paper used super resolution microscopy to assess the 
subcellular distributions of endogenous SUMO2/3 (and to a lesser 
extent SUMO1) and the SUMO-conjugating enzyme Ubc9 in cultured 
neurons (Colnaghi et al., 2019). Consistent with all previous studies, 
they report that the majority of SUMO and SUMOylation enzymes 
are present in the nucleus, but SUMO1, SUMO2/3 and Ubc9 were 
also detected in both pre- and post-synaptic compartments. More 
specifically, in primary hippocampal neurons, they showed that three 
separate antibodies raised against different regions of SUMO2/3 par-
tially colocalized with the pre- and post-synaptic markers synapto-
physin and PSD95 respectively (Colnaghi et al., 2019). Moreover, they 
also specifically excluded the possibility that the presence of synaptic 
SUMO proteins was because of synaptically localized mitochondria, 
which contain a number of known SUMO targets (Henley et al., 2018). 
These data lend further support to key roles of SUMOylation in the 
direct regulation of synaptic activity.
It has also been reported that activation of the metabotropic glu-
tamate receptor mGluR5, increases the synaptic residency time of the 
SUMO-conjugating enzyme Ubc9 by transiently restricting Ubc9 dif-
fusion out of the dendritic spine (Loriol et al., 2014). The mechanism 
underpinning this synaptic retention likely involves Ubc9 binding to 
PKC-phosphorylated synaptic substrates resulting in diffusional trap-
ping of Ubc9 and increased synaptic SUMOylation (Loriol et al., 2014). 
This activity-dependent recruitment and retention of Ubc9 in spines 
may facilitate the dynamic up-regulation of SUMOylation to modu-
late synaptic transmission and plasticity (Figure 1).
The diffusion properties of the SUMO protease SENP1 in in-
dividual hippocampal spines has also been investigated, and it was 
recently reported that this too is regulated by mGluR5 activity 
(Schorova et al., 2019). Similar to Ubc9, mGluR5 activation reduced 
diffusion and caused an accumulation of SENP1 in dendritic spines 
(Figure 1). The authors propose that the post-synaptic increases in 
both Ubc9 and SENP1 act synergistically to homeostatically regulate 
synaptic protein SUMOylation (Schorova et al., 2019). Indeed, sev-
eral SUMOylation enzymes, including SAE1, Ubc9 and SENP1, have 
been reported to undergo developmental and potassium chloride 
depolarization-dependent redistribution in neurons (Loriol, Khayachi, 
Poupon, Gwizdek, & Martin, 2013). However, many of the other phys-
iological and pathophysiologically relevant stimuli have not been in-
vestigated and exactly how neuronal activity leads to alterations in 
the localization of these enzymes, and the consequences for neuronal 
function, remain unclear.
Although primarily localized in the nucleus, SENP3 also has a wide-
spread distribution in neurons including localization at mitochondria 
and synapses (Guo et al., 2013). Moreover, levels of individual SENPs 
are differentially regulated. For instance levels of SENP1 are increased 
whereas levels of SENP3 are reduced in neurons during ischemic cell 
stress (Cimarosti et al., 2012; Guo et al., 2013; Guo, Wilkinson, Evans, 
Rubin, & Henley, 2017), indicating both proteins are dynamically reg-
ulated and that there may be a reciprocal relationship between the 
activity and/or levels of SENP1 and SENP3. It is well established 
that both in vitro and in vivo models of ischemia lead to enhanced 
SUMOylation, particularly by SUMO2/3 (for review see (Bernstock 
et al., 2019)). Since SENP1 deconjugates both SUMO1 and SUMO2/3, 
and SENP3 targets SUMO2/3 (Hickey, Wilson, & Hochstrasser, 2012), 
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how this reciprocal regulation leads to enhanced SUMO2/3 conjuga-
tion remains unclear, but it remains possible that they target different 
subsets of substrates, resulting in a net increase in SUMO2/3 conju-
gation driven by SENP3 loss (Guo et al., 2013), however this possi-
bility needs experimental confirmation. Moreover, how ischaemia 
alternately regulates SENP levels and activity, and how this shapes the 
profile of modified SUMO targets to induce the neuronal response to 
stress, has not yet been extensively investigated.
3.1 | SUMOylation of synaptic proteins
It was first reported that SUMOylation can regulate neurotransmit-
ter release from isolated synaptosomes (Feligioni, Nishimune, & 
Henley, 2009) and subsequent studies have shown that SUMOylation 
controls proteins essential for pre-synaptic neurotransmitter release, 
as well as post-synaptic receptors, ion channels and proteins integral 
to synaptic function (Table 1; for review see (Henley et al., 2014)). 
For example synapsin 1a is a component of the pre-synaptic SNARE 
machinery that modulates vesicle availability (Figure 1). Preventing 
synapsin 1a SUMOylation at Lys687 alters vesicle trafficking and ex-
ocytosis (Tang, Craig, & Henley, 2015). Furthermore, an autism and 
epilepsy-associated mutation in synapsin 1a (Fassio et al., 2011) re-
duces its SUMOylation and displays similar functional defects to non-
SUMOylatable synapsin 1a, suggesting defective SUMOylation may 
lead to synaptic dysfunction in these disorders (Tang et al., 2015).
Although changes in the synaptic surface expression of α-ami-
no-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptors 
F I G U R E  1   SUMOylation of synaptic receptor and receptor-associated proteins. Schematic summarizing the functional effects of 
SUMOylation and deSUMOylation on selected synaptic proteins. (a) SUMOylation of the pre-synaptic Synapsin 1a facilitates the re-
clustering/anchoring of synaptic vesicles after neurotransmitter release. (b) mGluR5-dependent synaptic trapping of Ubc9 (i) Activity-
induced PKC activation phosphorylates synaptic proteins. (ii) Ubc9 binding to phospho-proteins ‘traps’ Ubc9 in the synapse. (iii) 
Correspondingly, activation of mGluR5 increases dendritic SENP1, providing a homeostatic feedback mechanism. (c) SUMOylation of 
mGluR7 stabilizes its pre-synaptic surface expression. Glutamate activation of mGluR7 results in deSUMOylation and internalization. (d) 
PKC phosphorylation of the Kainate receptor subunit GluK2 leads to SUMOylation (i) and internalization (ii). PKC SUMOylation inhibits 
its kinase activity whereas SENP1 deSUMOylation of PKC enhances activity leading to phosphorylation of glycine receptor (GlyR) and 
facilitates internalization (iii). (e) mGluR1/5 activation enhances SUMOylation of FMRP, facilitating dissociation from mRNA granules (i) and 
leading to increased local translation (ii)
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(AMPARs) is a key aspect of plasticity in excitatory neurons, AMPAR 
subunits are not SUMOylated (Martin, Nishimune, Mellor, & 
Henley, 2007; Wilkinson, Nishimune, & Henley, 2008). However, 
theta burst stimulation, which induces long-term potentiation (LTP) 
in cultured slices, leads to an increase in SUMO2/3 conjugation 
(Lee et al., 2014), and chemically inducing LTP with glycine stimu-
lation in cultured neurons increases SUMO1 mRNA levels (Jaafari 
et al., 2013), indicating that plasticity induction can alter the protein 
SUMOylation pathway, in a manner dependent on the stimulation 
protocol and experimental system used. Furthermore, reducing 
SUMOylation by over-expressing the catalytic domain of SENP1 
or a dominant-negative mutant of Ubc9 interferes with AMPAR 
trafficking, plasticity and hippocampal-dependent learning (Jaafari 
et al., 2013; Lee et al., 2014) suggesting that proteins that mediate 
the activity-dependent sorting of AMPARs are under the control of 
the SUMOylation pathway.
3.2 | Synaptic neurotransmitter receptors and 
transporters
3.2.1 | G-protein-coupled receptors (GPCRs)
As set out in the examples cited below, there is increasing evidence 
that SUMOylation of G-protein-coupled receptors modulates down-
stream Ca2+ signalling and neurotransmitter release.
3.2.2 | mGluR7 and mGluR8
Metabotropic glutamate receptors (mGluRs) are class C, G-protein-
coupled receptors that play a role in modulating synaptic transmis-
sion and neuronal excitability. They are divided into three groups 
and have been reviewed extensively (for example see (Niswender & 
Conn, 2010)). Group III mGluRs (mGluR4 and mGluR6-8) are pre-syn-
aptic and suppress excitation. mGluR7 is an autoreceptor that inhib-
its glutamate release to modulate excitatory neurotransmission and 
synaptic plasticity (Enz, 2012; Mukherjee & Manahan-Vaughan, 2013) 
(Figure 1). Several studies have reported an interaction between 
Group III mGluRs and SUMO pathway proteins, and demonstrated 
SUMOylation of their intracellular C-termini in vitro (Dutting, Schroder-
Kress, Sticht, & Enz, 2011; Tang, El Far, Betz, & Scheschonka, 2005; 
Wilkinson et al., 2008). In clonal cell line expression systems mGluR8b 
is SUMOylated at Lys882 and Lys903, whereas mGluR7 is SUMOylated 
at Lys889 (Dutting et al., 2011; Wilkinson & Henley, 2011). More re-
cently, SUMOylation of full-length mGluR7 at Lys889 has been con-
firmed in brain and primary cortical neurons, and SUMOylation is 
decreased by the mGluR7 agonist L-AP4 (Choi et al., 2016). Moreover, a 
non-SUMOylatable mutant of mGluR7, or over-expression of SENP1 in 
hippocampal neurons, caused enhanced mGluR7 internalization, sug-
gesting that SUMOylation can stabilize surface expression of mGluR7 
(Choi et al., 2016) (Figure 1).
3.2.3 | M1 muscarinic acetylcholine receptor (M1 
mAChR)
Another GCPR proposed as a SUMO target is the M1 muscarinic ace-
tylcholine receptor (M1 mAChR) (Xu et al., 2019) which plays impor-
tant roles in learning and memory (Kruse et al., 2014). M1 mAChR has 
been reported to be SUMOylated by SUMO1 at K327, which is situ-
ated in the intracellular loop 3, and receptor activation with carbachol 
decreases this SUMO1-ylation. However, it is notable that the SUMO 
conjugated M1 appears to resolve at the same molecular weight as 
non-SUMOylated M1, which is difficult to explain. Nonetheless, 
these authors conclude that SUMO1-ylation increases M1 mAChR 
ligand-binding affinity, signalling and receptor endocytosis. Mutation 
of K327 to arginine attenuated M1 mAChR SUMOylation by SUMO1 
and decreased ligand-binding affinity and signal transduction. 
Molecular dynamics simulations suggest SUMOylation regulates 
mAChR by stabilizing the receptor in an active-state conformation 
(Xu et al., 2019).
3.2.4 | Kainate receptors (KARs), Protein Kinase C 
(PKC) and Glycine receptors (GlyRs)
Kainate receptors are a subclass of ionotropic glutamate receptor 
that play diverse roles in neuronal excitability, pre-synaptic release 
and post-synaptic signalling (Evans, Gurung, Henley, Nakamura, & 
Wilkinson, 2019). Several studies have shown that the KAR subu-
nit GluK2 is SUMOylated at a single C-terminal lysine, K886, in an 
agonist-dependent manner, resulting in endocytosis of GluK2-
containing KARs (Figure 1, for reviews see (Pahl, Tapken, Haering, & 
Hollmann, 2014; Henley et al., 2018)). Intriguingly, it has also been re-
ported that GluK2 internalization following SUMOylation promotes 
binding to mixed lineage kinase 3 (MLK3) and activation of the MLK3-
c-Jun N-terminal kinase 3 (JNK3) pathway, which could contribute to 
neuronal loss in ischemia (Zhu, Xu, Du, & Hou, 2012).
Another interesting observation is that KAR activation causes 
endocytosis of GlyRs, which are important inhibitory receptors that 
have been extensively studied in spinal cord. This effect is calcium and 
PKC-dependent. Moreover, the authors show that PKC is a SUMO 
substrate and that SUMOylation inhibits its activity. Furthermore, 
KAR-evoked GlyR endocytosis requires SENP1-mediated deSUMOy-
lation of PKC, leading to enhanced phosphorylation of GlyR (Sun 
et al., 2014) (Figure 1).
More recently, the same group also reported that SUMOylation 
of PKC inhibits the binding of 14–3-3tau to GluK2 by reducing GluK2 
phosphorylation (Li, Wang, Zhu, Zhou, & Li, 2017). 14–3-3tau is a con-
served family of regulatory proteins that bind to a wide range of targets, 
and binding to GluK2 contributes to the slow decay kinetics of KAR-
mediated excitatory post-synaptic currents (EPSCs) (Sun et al., 2013). 
Together, these studies suggest that PKC SUMOylation may be an im-
portant modulator of synaptic (and other) proteins by regulating PKC 
phosphorylation. Indeed, given that SUMOylation of GluK2 is itself 
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promoted by GluK2 phosphorylation by PKC (Chamberlain et al., 2012; 
Konopacki et al., 2011), and the role of PKC in stabilizing the synaptic 
residence time of Ubc9 (Loriol et al., 2014), these data suggest a sophis-
ticated regulatory interplay between SUMOylation and PKC.
3.2.5 | Dopamine transporter (DAT)
Dopamine transporter (DAT) reuptakes released dopamine into 
the pre-synaptic terminal to terminate dopamine neurotransmis-
sion. DAT function is influenced by cocaine and amphetamine and 
its dysfunction has been strongly implicated in neurological condi-
tions including autism spectrum disorders, attention-deficit hyper-
activity disorder (ADHD) and Parkinson's disease (German, Baladi, 
McFadden, Hanson, & Fleckenstein, 2015). The surface expression 
of DAT is critical for its function and a recent study has reported 
that SUMO1-ylation acts to enhance the total levels of DAT in the 
plasma membrane (Cartier et al., 2019). Imaging and western blot as-
says revealed the close association of SUMO1 and DAT, and over-
expression of SUMO1 or Ubc9 enhanced DAT surface expression and 
stability. Moreover, expression of SUMO1 reduced DAT ubiquitina-
tion. Conversely, Ubc9 knock-down caused a decrease in SUMO-DAT 
association and an increase in DAT degradation (Cartier et al., 2019). 
However, because site directed mutagenesis of lysines that are pre-
dicted as SUMOylation sites has not been reported, it has not yet 
been unequivocally established whether it is covalent SUMO1 con-
jugation or non-covalent association with SUMO or a SUMOylated 
interactor through a SUMO interaction motif (SIM) that regulates 
DAT surface expression and turnover. Indeed, one of the three pre-
dicted SIMs contain a lysine (K35) that is targeted for ubiquitination 
(Miranda, Dionne, Sorkina, & Sorkin, 2007; Miranda, Wu, Sorkina, 
Korstjens, & Sorkin, 2005) suggesting that SUMO binding might be 
sufficient to impair ubiquitin-mediated degradation. Nonetheless, 
these data indicate a role for SUMO in the regulation of DAT and, 
consequently, in dopamine signalling.
4  | Direct regulat ion of ion channels by 
SUMOylation
Given the diversity and number of reports on ion channel subunit 
SUMOylation it seems likely that this post-translational modification, 
through altering ion channel conformation, acting to block the chan-
nel pore, or enhancing or inhibiting protein interactions, may repre-
sent a common mechanism for their functional regulation (for recent 
review see (Benson, Iniguez-Lluhi, & Martens, 2017)).
For example, a recent study using the lateral pyloric neuron of 
spiny lobsters showed that SUMO conjugation and deconjugation is 
synergistically regulated to control the opposing hyperpolarization ac-
tivated current (Ih) mediated by hyperpolarization-activated cyclic nu-
cleotide–gated (HCN) channels, and the transient potassium current (IA) 
mediated by Kv4 channels (Parker, Forster, & Baro, 2019). These data 
suggest that activity-dependent SUMOylation can rapidly adjust ionic 
current densities to homeostatically control the balance of neuronal 
excitation by altering surface expression and biophysical properties 
(Parker et al., 2016; Welch, Forster, Atlas, & Baro, 2019), highlighting 
SUMOylation as a potential ‘key coordinator’ of neuronal excitability.
4.1 | K+ and Na+ ion channels
The two-pore potassium channel, K2P1, which acts to suppress neu-
ronal excitability, was the first identified ion channel to be SUMOylated. 
In this case, constitutive SUMOylation prevents channel activity 
(Rajan, Plant, Rabin, Butler, & Goldstein, 2005). Subsequent studies 
reported that multiple voltage-dependent potassium (Kv) channels are 
also SUMOylated. SUMOylation of Kv1.5 regulates channel inactiva-
tion (Benson et al., 2007), indicating that while SUMOylation entirely 
inhibits K+ conductance through K2P1, the effects of SUMOylation of 
Kv1.5 are more nuanced. It has also been reported that Kv4.2 channels 
are SUMOylated at two distinct sites (K437 and K579) which increase 
surface expression and decrease potassium current maximal conduct-
ance respectively (Welch et al., 2019). Additionally, SUMOylation de-
creases Kv2.1 (Plant, Dowdell, Dementieva, Marks, & Goldstein, 2011), 
KV7.2 (Qi et al., 2014), KV7.1 (Xiong et al., 2017) and KV11.1 (Steffensen, 
Andersen, Mutsaers, Mujezinovic, & Schmitt, 2018) currents, high-
lighting this modification as general regulator of potassium channel 
function.
Conversely, SUMOylation of the voltage-dependent sodium 
channel NaV1.2 increases Na
+ currents (Plant, Marks, & Goldstein, 
2016). Thus, the current literature indicates that the overarching ef-
fect of ion channel SUMOylation is to increase neuronal excitability 
by suppressing K+ channels and enhancing Na+ channels (Figure 2). 
Since SUMOylation of these channels is likely differentially regulated 
under different stimulation conditions, how SUMOylation coordi-
nates and integrates their activity to control neuronal excitability, 
analogous to its homeostatic regulation of the Ih and IA currents, is an 
important question for future research.
4.2 | Ligand-gated non-selective cation 
channel TRPV1
TRPV1 (also known as the capsaicin receptor, vanilloid receptor 
1) is abundantly expressed in dorsal root ganglia (DRG) neurons 
(Andresen, 2019), and is necessary for the development of inflam-
matory thermal hyperalgesia, a phenomenon whereby inflammation 
leads to enhanced sensitivity to thermal stimuli. TRPV1 is a SUMO 
substrate and its SUMOylation at K822 in DRG neurons is enhanced 
by peripheral inflammation (Wang et al., 2018). SUMOylation at 
K822 lowers the threshold for TRPV1 channel activation by heat, in-
creasing sensitivity to thermal stimuli at the inflamed site (Figure 2). 
Conditional knockout mice in which SENP1 was ablated selectively 
from DRG neurons to prolong protein SUMOylation displayed greater 
inflammatory thermal hyperalgesia (Wang et al., 2018). Conversely, 
TRPV1 knockout mice are resistant to inflammatory thermal 
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hyperalgesia. This is reversed by virally mediated expression of wild-
type, but not SUMOylation-deficient (K822R), TRPV1 in DRG neu-
rons. These data suggest that SUMO1-ylation of TRPV1 sensitizes the 
channel to heat activation (Wang et al., 2018), and provides an elegant 
example of the importance of SUMOylation of an individual target 
protein in underpinning a complex physiological behaviour.
5  | Indirect regulat ion of ion channels by 
SUMOylation
5.1 | Collapsin response mediator protein 2 (CRMP2)
Collapsin response mediator protein 2 (CRMP2) is a member of a 
cytosolic family of proteins that dynamically regulate microtubule 
stability and is involved in axon–dendrite polarity, dendritic spine de-
velopment and synaptic plasticity, and its dysfunction is strongly im-
plicated in neuropsychiatric disease (Quach, Honnorat, Kolattukudy, 
Khanna, & Duchemin, 2015). Moreover, CRMP2 appears to play a 
pivotal role in the assembly and function of channel complexes in-
cluding, but not limited to, voltage-gated ion channel assemblies in-
volved in pain transmission (Chew & Khanna, 2018).
CRMP2 has been identified as a SUMO substrate and, initially, 
SUMOylation of CRMP2 was shown to decrease calcium influx 
mediated by CaV2.2 calcium channels (Ju et al., 2013) but has now 
been most extensively studied for its regulation of NaV1.7 sodium 
channels (for recent review see (Chew & Khanna, 2018)). The impor-
tance of CRMP2 in pain transmission is well established and is the 
subject of concerted efforts to determine if it is a druggable thera-
peutic target (Chew, Bellampalli, Dustrude, & Khanna, 2019; Chew & 
Khanna, 2018).
The first study indicating that SUMOylation of CRMP2 regulates 
sodium channel trafficking and biophysical properties showed that 
expression of a non-SUMOylatable CRMP2 (CRMP2-K374A) reduced 
NaV1.7 current density and surface expression in the catecholamine 
A differentiated neuroblastoma cell line, and reduced sodium cur-
rent density in DRG neurons. These effects on NaV1.7 current den-
sity and surface expression could also be reproduced by promoting 
F I G U R E  2   Ion channel SUMOylation. (a) Overall, SUMOylation of potassium channels reduces conductance, whereas SUMOylation of 
sodium channels increases conductance. (b) Cdk5 phosphorylation enhances CRMP2 SUMOylation, whereas Fyn phosphorylation antagonizes 
its SUMOylation. SUMOylated CRMP2 increases NaV1.7 sodium channel surface expression and current density. (c) Inflammation increases 
TRPV1 channel SUMOylation, which reduces the threshold of channel activation by heat and increases pain sensation
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deSUMOylation with SENP1 and SENP2 in CRMP2-expressing cells 
(Dustrude, Wilson, Ju, Xiao, & Khanna, 2013).
A later study showed that expression of a non-SUMOylatable 
point mutant (K374A) of CRMP2 reduces CRMP2 binding to NaV1.7 
and promotes clathrin-dependent NaV1.7 internalization (Dustrude 
et al., 2016). They also observed that interplay between phosphoryla-
tion and SUMOylation of CRMP2 controls CRMP2 SUMOylation and 
NaV1.7 trafficking. Cyclin-dependent kinase 5 (CK5)-mediated phos-
phorylation of CRMP2 at S522 enhances its SUMOylation, whereas 
phosphorylation by Fyn at Y32 antagonizes CRMP2 SUMOylation and 
promotes NaV1.7 internalization, leading to decreased NaV1.7 mem-
brane localization, current density and neuronal excitability (Figure 2).
CRMP2 SUMOylation is increased during an in vivo model of neu-
ropathic pain, consistent with it increasing NaV1.7 surface expression 
(Moutal et al., 2018). Experiments expressing either CRMP2 WT or 
CRMP2 K374A in vivo showed that CRMP2 K374A significantly re-
versed mechanical allodynia—pain caused by a stimuli that does not 
normally illicit a painful response—in a spared nerve injury model of 
neuropathic pain, suggestive of a functional link between CRMP2 
SUMOylation and pain (Moutal et al., 2018). Intriguingly, a TAT-peptide 
that interrupts SUMOylation of CRMP2 causes similar suppression of 
NaV1.7 currents. Infusion of this peptide reversed persistent hyper-
sensitivity in an in vivo spinal nerve injury model of neuropathic pain 
(Francois-Moutal et al., 2018 et al. 2018), providing an exciting proof-
of-concept for the strategy of using cell-permeable peptides targeting 
SUMOylation of individual substrates for therapeutic benefit.
5.1.1 | CRMP2 and dendritic spines
It has been reported recently that CRMP2 over-expression increases 
the size and frequency of miniature excitatory post-synaptic cur-
rents (mEPSCs), the number of PSD95 puncta and the density of 
mature, mushroom-shaped spines in hippocampal neurons (Zhang 
et al., 2018). Furthermore, preventing phosphorylation of CRMP2 at 
T514, or SUMOylation at K374, further enhanced the frequency and 
amplitude of mEPSCs and the number of mature spines. Surprisingly, 
however, these authors found no evidence of interplay between these 
two post-translational modifications, suggesting that they may act via 
separate pathways to regulate spine maturation (Zhang et al., 2018).
6  | SUMOylation of other proteins involved 
in the regulat ion of synaptic function
6.1 | Arc
Expression of the cytoskeleton-associated immediate early gene 
Arc is rapidly induced by neuronal activity to participate in vari-
ous forms of synaptic plasticity, including LTP, LTD and homeo-
static scaling (Carmichael & Henley, 2018). It plays pivotal roles in 
regulating AMPAR trafficking (Chowdhury et al., 2006; Shepherd 
et al., 2006), memory formation (Zhang et al., 2019) and trafficking 
of the Alzheimer's associated proteins amyloid precursor protein and 
beta-site amyloid precursor protein cleaving enzyme 1 (β-secretase 
1) (Wu et al., 2011).
Arc is subject to multiple post-translational modifications includ-
ing phosphorylation, ubiquitination and SUMOylation (Carmichael & 
Henley, 2018; Mabb & Ehlers, 2018). In particular, Arc SUMOylation has 
been proposed as an important determinant of protein-protein interac-
tions and function in homeostatic synaptic scaling (Craig & Henley, 2012) 
and LTP induction in vivo (Nair et al., 2017). Arc synthesized during the 
maintenance phase of LTP induced in vivo undergoes enhanced SUMO-1-
ylation, which is prevented if LTP maintenance is inhibited (Nair et al., 2017). 
SUMOylated Arc was detected in synaptosomal and cytoskeletal fractions 
and complexes with the F-actin-binding protein drebrin A, a regulator of 
dendritic spine cytoskeletal dynamics (Shirao et al., 2017), raising the pos-
sibility that newly synthesized Arc is SUMOylated and targeted for actin 
cytoskeletal regulation during a LTP (Nair et al., 2017); Figure 3.
6.1.1 | FMRP
Group I mGluRs (mGluR1 and mGluR5) are mainly post-synaptic and 
activate a range of downstream pathways. Activation of Group I 
mGluRs induces a form of LTD and their dysfunction has been strongly 
implicated in disease (Ribeiro, Paquet, Cregan, & Ferguson, 2010). 
Importantly, in addition to regulating the synaptic retention of 
Ubc9 and SENP1 discussed previously (Loriol et al., 2014; Schorova 
et al., 2019), mGluR5 activation increases SUMOylation of fragile X 
mental retardation protein (FMRP), which leads to the dissociation of 
FMRP from dendritic mRNA granules to promote spine maturation 
(Khayachi et al., 2018) (Figure 1). This is important because abnormal 
dendritic spine maturation leads to Fragile X syndrome, a major cause 
of intellectual disability and the most well characterized monogenic 
cause of autism. Thus, through control of FMRP, SUMOylation po-
tentially plays key roles in synapse maturation and neuronal network 
formation (Khayachi et al., 2018). Indeed, a role for SUMOylation in 
controlling dendritic spine number has also been shown in mice over-
expressing SUMO1 (Matsuzaki et al., 2015). Cortical and hippocampal 
neurons from SUMO1 over-expressing mice exhibited reduced spine 
density, and mice displayed defective fear conditioning responses 
(Matsuzaki et al., 2015). While this may seem inconsistent with the 
requirement for FMRP SUMOylation to promote spine maturation, 
it is important to note that SUMO1 over-expression will lead to en-
hanced SUMOylation of many substrates, some of which may have ef-
fects on spine number. Thus, while SUMOylation of FMRP promotes 
spine maturation, the net effect of globally enhancing SUMO1-ylation 
is decreased spine number. However, the identity of these other 
SUMOylated spine regulators remains to be determined.
6.2 | α-SYNUCLEIN
The pre-synaptically localized protein α-synuclein has been pro-
posed to play roles in regulating the size of the synaptic vesicle pool 
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and assembly of the neurotransmitter release machinery (Burre 
et al., 2010). α-Synuclein is also the focus of concerted research 
because of its association with both sporadic and familial forms 
of Parkinson's Disease (PD). α-Synuclein-containing aggregates 
known as Lewy Bodies are a hallmark of PD, and, so far, 6 muta-
tions in α-synuclein have been associated with familial PD (Dehay 
& Fernagut, 2016). α-Synuclein was first identified as a SUMO sub-
strate by Dorval and Fraser (Dorval & Fraser, 2006), and subsequent 
work demonstrated that 11 of the 15 lysines in α-synuclein can 
be SUMOylated (Kim et al., 2011; Krumova et al., 2011; Oh, Kim, 
Mouradian, & Chung, 2011; Rousseaux, de Haro, & Lasagna-Reeves, 
2016; Rousseaux et al., 2018). SUMOylation has been variously pro-
posed to regulate α-synuclein localization, turnover, aggregation 
and toxicity (Kim et al., 2011; Krumova et al., 2011; Oh et al., 2011; 
Rousseaux et al., 2016, 2018), suggesting that many aspects of 
α-synuclein behaviour are under the control of SUMOylation, po-
tentially depending on the specific lysines modified, the cellular 
context, and experimental system used. Most recently, interplay 
between SUMOylation and ubiquitination has been shown to con-
trol α-synuclein turnover (Rott et al., 2017). Rott et al identified 
PIAS2 as an E3 ligase that promotes α-synuclein SUMOylation. 
Expression of PIAS2 in HEK293 cells also reduced mono-ubiq-
uitination of α-synuclein and enhanced its stability, suggesting 
SUMOylation negatively regulates ubiquitin-mediated α-synuclein 
degradation. Interestingly, three PD-associated α-synuclein mutants 
displayed enhanced SUMOylation, which was promoted by PIAS2, 
leading to the formation of α-synuclein aggregates. Moreover, lev-
els of PIAS2, and SUMOylated α-synuclein, were increased in the 
cerebral cortex of PD patients who progressed to dementia (Rott 
et al., 2017). Together, these data suggest that enhanced PIAS2 
levels in PD may contribute to disease progression through enhanc-
ing the SUMOylation and aggregation of α-synuclein. Moreover, 
it remains possible that SUMOylation also regulates the proposed 
functions of α-synuclein in pre-synaptic neurotransmitter release 
under non-pathological conditions, although this has not yet been 
investigated.
F I G U R E  3   SUMOylation of GTPases during synaptic plasticity. During LTP, SUMOylated Arc associates with drebrin A, an actin-binding 
protein. This impairs α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor (AMPAR) internalization to promote increased surface 
expression. (a) CC2D1A deletion leads to reduced SENP 1/3 levels, which in turn, regulates the SUMOylation of Rac1. SUMOylated Rac1 
enhanced Rac1 activity. Rac1 inhibits cofilin activity, which severs F-actin. SUMOylation of Rac1 enhances activity, thus indirectly promotes 
actin stabilization by blocking cofilin in dendritic spine formation
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6.3 | Neuronal nitric oxide synthase
Neuronal nitric oxide synthase (nNOS) and nitric oxide (NO) signalling 
can mediate long-lasting synaptic plasticity. A very recent paper has 
shown that NMDAR stimulation promotes SUMO1-ylation of nNOS 
at K725 and K739. nNOS SUMOylation enhances its phosphoryla-
tion at S1412, which increases NO production (Du et al., 2020). The 
authors reported that nNOS SUMOylation is required for NMDAR-
evoked activation of ERK and hippocampal LTP induction, and that 
blocking activity-induced nNOS SUMOylation suppressed LTP-
related expression of Arc and brain-derived neurotrophic factor (Du 
et al., 2020).
6.4 | Small GTPases
Small GTPases function as ‘molecular switches’ to coordinate a mul-
titude of cellular signalling pathways (Hall, 1990). In neurons, several 
small GTPases play crucial roles in controlling neuronal morphol-
ogy, synapse formation (Gonzalez-Billault et al., 2012; Woolfrey 
& Srivastava, 2016), and regulating the synaptic actin cytoskel-
eton and post-synaptic AMPAR trafficking during synaptic plastic-
ity (Hotulainen & Hoogenraad, 2010; Kruijssen & Wierenga, 2019; 
Patterson, Szatmari, & Yasuda, 2010).
6.4.1 | Rac1
Rac1, and the related GTPases RhoA and Cdc42, have been identified 
as causal signals for the initiation of changes in spine structure and 
structural LTP (Hedrick et al., 2016). The stabilization of the f-actin 
cytoskeleton is pivotal to structural remodelling of dendritic spines 
late phase LTP and this is regulated in part by preventing the disas-
sembly of actin filaments by cofilin A (Bosch et al., 2014; Hlushchenko, 
Koskinen, & Hotulainen, 2016). Rac 1 inhibits actin depolymerization 
by cofilin indicating that Rac 1-cofilin signalling plays a key role in 
spine morphology (Pyronneau et al., 2017) (Figure 3).
Rac1 was the first member of the Ras family GTPases shown to 
be SUMOylated (Castillo-Lluva et al., 2010). SUMOylation enhances 
Rac1 activation (Castillo-Lluva et al., 2010), and subsequent work 
has demonstrated a link between Rac1 SUMOylation, LTP and per-
formance in object location memory tests in vivo (Yang, Yu, Wen, 
Ling, & Hsu, 2019). Rac1 SUMOylation is at least partly regulated by 
expression levels of SENP1 and SENP3, which are in turn regulated 
by the coiled-coil and C2 domain-containing 1A (CC2D1A) protein 
(Yang et al., 2019). CC2D1A has multiple roles including acting as a 
transcriptional repressor (Szewczyk et al., 2010) and as a scaffold/
regulator of protein kinases (Al-Tawashi, Jung, Liu, Su, & Qin, 2012; 
Nakamura, Naito, Tsuruo, & Fujita, 2008), and mutations in CC2D1A 
cause autosomal recessive non-syndromic intellectual disability (Al-
Tawashi et al., 2012; Nakamura et al., 2008). Conditional knock-out 
of CC2D1A in excitatory neurons results in impaired hippocam-
pal LTP maintenance and reduced performance in object location 
memory tests (Yang et al., 2019). Intriguingly, loss of CC2D1A reduces 
SENP1/3 levels, which enhances SUMOylation and activation of 
Rac1. Since LTP and object location memory can be rescued in these 
mice by pharmacological inhibition of Rac1, the authors propose that 
CC2D1A controls synaptic plasticity and memory by regulating SENP 
levels and SUMOylation of Rac1 (Yang et al., 2019) (Figure 3).
6.4.2 | Ras
Ras activation drives the delivery and surface expression of AMPARs 
during LTP (Zhu, Qin, Zhao, Van Aelst, & Malinow, 2002). All three 
isoforms of Ras (H-Ras, K-Ras and N-Ras) can be modified by 
SUMO2/3 at a single lysine, K42 (Choi, Chen, Philips, & Dai, 2018). 
SUMOylation of K-Ras is enhanced by the E3 ligase PIASγ (Choi, 
Chen, et al., 2018), and mutation of the SUMO acceptor site leads 
to a reduction in activation of the downstream targets of Ras, c-Raf, 
MAPK/ERK kinase 2 and ERK (Choi, Philips, Chen, Lu, & Dai, 2018), 
suggesting SUMOylation of Ras promotes Ras signalling. While the 
roles of Ras SUMOylation have not yet been directly investigated in 
neurons, these wider findings offer the intriguing possibility that Ras 
SUMOylation may play a role in LTP through regulation of AMPAR 
trafficking.
6.4.3 | Rhes-mediated SUMOylation of Huntingtin
Ras homolog enriched in the striatum (Rhes) (Falk et al., 1999) is a 
small GTPase that also functions as a SUMO E3 ligase to enhance 
SUMOylation of poly-Q expanded mutant Huntingtin (mHTT), the 
protein that is the cause of the lethal neurodegenerative disorder 
Huntington's disease (HD) (Harrison & Lahoste, 2013). Although HD 
is characterized by aggregates of poly-Q expanded mHtt, evidence 
suggests that the soluble form represents the toxic species (Arrasate 
& Finkbeiner, 2012; Harrison & Lahoste, 2013). SUMOylation reduces 
mHtt aggregation by enhancing its solubility (Steffan et al., 2004; 
Subramaniam, Sixt, Barrow, & Snyder, 2009). Interestingly, Rhes only 
promotes SUMOylation of mHtt, not wild-type Htt, thereby reducing 
aggregation of mHtt and increasing the amounts of the toxic soluble 
form (Subramaniam et al., 2009, 2010; Subramaniam & Snyder, 2011). 
Thus, the high expression of Rhes may underlie the sensitivity of 
the striatum to neurodegeneration in HD. Based on this hypothesis, 
bioinformatic analyses and molecular modelling of the interaction 
domains between Rhes, mHtt and Ubc9 are currently being used to 
design inhibitory peptides to combat HD (Carbo et al., 2019).
6.4.4 | Rab17
Another small GTPase involved in polarized trafficking, dendritic 
morphogenesis and post-synaptic development in hippocampal neu-
rons is Rab17 (Mori, Fukuda, & Henley, 2014; Mori, Matsui, Furutani, 
Yoshihara, & Fukuda, 2012). In cultured neurons, Rab17 co-localizes 
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with Syntaxin-4, a post-synaptic SNARE protein that has been im-
plicated in the exocytosis of AMPARs in dendritic spines (Kennedy, 
Davison, Robinson, & Ehlers, 2010; Mori et al., 2014). Rab17 knock-
down significantly reduced surface expression of the KAR subunit 
GluK2, but did not affect the AMPAR subunit GluA1, and causes 
Syntaxin-4 redistribution away from dendrites and into axons in 
developing hippocampal neurons (Mori et al., 2014). Moreover, 
over-expression of constitutively active Rab17 promoted dendritic 
surface expression of GluK2 by enhancing Syntaxin-4 translocation 
to dendrites. These data suggest that Rab17 mediates the dendritic 
trafficking of Syntaxin-4 to selectively regulate dendritic surface in-
sertion of GluK2-containing KARs in rat hippocampal neurons (Mori 
et al., 2014). Intriguingly, in analogous studies, mono-SUMOylation of 
Rab17 has also been shown to selectively promote its interaction with 
Syntaxin-2 in polarized liver cells, although these authors did not de-
tect an effect of Rab17 SUMOylation on interaction with Syntaxin-4 
in these cells. Expression of non-SUMOylatable Rab17(K68R) redis-
tributes Syntaxin-2 from the apical membrane to subapical puncta. 
Furthermore, preventing Rab17 SUMOylation reduced apical vesicle 
docking (Striz & Tuma, 2016) which is required for transcytotic vesicle 
delivery (Striz, Stephan, Lopez-Coral, & Tuma, 2018). To our knowl-
edge, the role(s) of Rab17 SUMOylation in neurons has not been ex-
plored, but these findings suggest SUMOylation may play a role in 
the polarized insertion of neurotransmitter proteins into the neuronal 
membrane.
6.5 | Regulation of local dendritic protein 
synthesis; CPEB3
LTP is maintained and memory is encoded by the local synthesis 
of essential synaptic proteins (Kandel, Dudai, & Mayford, 2014). 
This local protein synthesis is regulated by cytoplasmic polyade-
nylation element-binding protein 3 (CPEB3), which exists in either 
a soluble inactive form, or an aggregated, insoluble, active form 
(Fioriti et al., 2015). Under basal conditions CPEB3 is SUMOylated 
by SUMO2/3 and acts as a local translational repressor (Drisaldi 
et al., 2015). However, following stimulation of hippocampal neu-
rons with glycine to chemically induce LTP, CPEB3 is rapidly deSU-
MOylated, which allows it to oligomerize, aggregate and regulate 
translation of its target proteins Intriguingly, SUMO2 mRNA is also 
a target of CPEB3, consistent with a negative regulatory feedback 
mechanism in which CPEB3 drives expression of SUMO2, presum-
ably limiting the extent and duration of CPEB3 activity (Drisaldi 
et al., 2015). A more recent study has examined in detail how 
SUMOylation of CPEB3 allows it to switch from a repressor to an 
activator of local translation (Ford, Ling, Kandel, & Fioriti, 2019). 
Ford et al. demonstrated that under basal conditions, SUMOylated 
CPEB3 is localized to membraneless cytoplasmic processing bodies 
(P-bodies) that contain translationally repressed mRNAs. Following 
stimulation, CPEB3 is deSUMOylated and recruited into polysomes 
to actively translate target mRNAs (Ford et al., 2019). Together, these 
data show that dendritic SUMOylation acts as a negative regulator 
of CPEB3 aggregation, and that activity-dependent deSUMOylation 
of CPEB3 is required for the translation of its target mRNAs during 
synaptic plasticity.
7  | CONCLUSIONS AND OUTLOOK
In addition to the important roles of nuclear SUMOylation in neu-
rons, there is substantial, diverse and compelling evidence that 
SUMOylation of proteins outside the nucleus regulates synaptic ac-
tivity, plasticity and neuronal excitability. The direct SUMOylation 
of proteins at, or close to, the synapse has been questioned (Daniel 
et al., 2017; Tirard et al., 2012) [but see (Henley et al., 2018; Wilkinson 
et al., 2017)]. However, as evidenced by the examples cited here, we 
believe that the essential roles of SUMOylation of synaptic and syn-
apse-associated proteins on neurotransmission, synaptic plasticity 
and memory is well established.
Nonetheless, there is still a great deal we do not know about the 
roles of SUMOylation in the brain. Recent advances in the large-scale 
identification of SUMO substrates by mass spectrometry (Hendriks 
& Vertegaal, 2016) will undoubtedly advance the field. We anticipate 
future studies will provide further evidence for the breadth of neu-
ronal proteins, both nuclear and extranuclear, that are modified by 
SUMO.
Moreover, while an expanding repertoire of synaptic and syn-
apse-associated proteins has, and continues to be, identified as 
SUMO substrates, the regulatory mechanisms involved remain 
elusive. For example, how are the restricted set of enzymes that 
conjugate or remove SUMO from target proteins controlled to or-
chestrate the differential modification of these substrates under 
basal and activity-dependent conditions? For many substrates, 
SUMOylation is regulated by interplay with other post-transla-
tional modifications, including phosphorylation and ubiquitina-
tion (Wilkinson & Henley, 2010). Given the well-established role 
of these post-translational modifications in plasticity (Widagdo, 
Guntupalli, Jang, & Anggono, 2017; Woolfrey & Dell'Acqua, 2015), 
it seems highly likely that their interaction with SUMOylation acts 
to tune synaptic responsiveness. Indeed, whether synapses consti-
tute a site of ‘group modification’, whereby a multitude of SUMO 
substrates are dynamically modified in a restricted cellular loca-
tion, as has been demonstrated at sites of DNA strand breaks in 
non-neuronal cells (Psakhye & Jentsch, 2012), represents an ex-
citing possibility for future investigation. Finally, given the number 
of neuronal disease-associated proteins modified by SUMO, the 
role of global SUMOylation in cell stress responses, and reports 
of perturbed SUMOylation in a number of disease states (Henley 
et al., 2014), targeting the SUMOylation pathway for therapeutic 
benefit in disorders of the nervous system represents an attractive 
possibility that is being actively investigated in a number of con-
texts. Addressing these questions will undoubtedly advance under-
standing of the mechanisms and multiple roles of neuronal protein 
SUMOylation and will provide exciting and important new insights 
into neuronal function and dysfunction.
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